DeepMed Research

Glycerin

Generic Name: Glycerin

Brand Names: Clear Eyes Cooling Comfort, Clear Eyes Redness Relief Reformulated Nov 2011, Fleet Mineral Oil, Genteal Tears, Glycerolyte 57, Pedia-lax Liquid, Preparation H Cream, Procalamine 3, Refresh Optive Advanced, Refresh Optive Extended Therapy, Synovisol, Tears Lubricant

Drug Type: Small Molecule

Chemical Formula: C_₃H_₈O_₃

CAS Number: 56-81-5

Unique Ingredient Identifier: PDC6A3C0OX

Background: A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.

Indication: It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent.

Associated Conditions: Cold Sore, Constipation, Dry Mouth, Dry Skin, Dry throat, Edema of the cerebrum, Increase in Intracranial Pressure (ICP), Occasional Constipation, Ocular Discomfort, Ocular Hypertension, Ocular Irritation, Skin Infections, Sore Throat, Mouth soreness, Sensation of burning in the eyes

Associated Therapies: Bowel preparation therapy, Topical Antisepsis, Skin protection

Clinical Trials

Lactate and Glycerol Contribution to Gluconeogenesis

Phase 1

Not yet recruiting

Conditions: Type 2 Diabetes
Obesity
Healthy

Interventions: Drug: Glycerol
Drug: Glucose
Drug: Lactate

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-13

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 48

Registration Number: NCT06955130

The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow

Phase 4

Completed

Conditions: Coronary Arterial Disease (CAD)
Angina (Stable)

Interventions: Drug: Glycerin trinitrate (GTN)
Drug: Saline (NaCl 0,9 %) (placebo)

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-28

Lead Sponsor: VZW Cardiovascular Research Center Aalst

Target Recruit Count: 40

Registration Number: NCT06823843

Locations: 🇧🇪
OLV Cardiovascular Center Aalst, Aalst, Flanders, Belgium

Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)

Phase 2

Not yet recruiting

Conditions: Pyruvate Dehydrogenase Complex Deficiency Disease

Interventions: Drug: Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

First Posted Date: 2025-03-20

Last Posted Date: 2025-05-02

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 15

Registration Number: NCT06887777

Locations: 🇫🇷
Hôpital Universitaire Necker - Enfants Malades, Paris, France

Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats

Phase 4

Not yet recruiting

Conditions: Rhabdomyolysis

Interventions: Diagnostic Test: iron
Drug: Lactoferrin
Diagnostic Test: MDA, TAC, and GSH
Diagnostic Test: Nrf2
Diagnostic Test: AMPK
Diagnostic Test: HO-1
Drug: glycerin

First Posted Date: 2024-07-09

Last Posted Date: 2024-10-01

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 24

Registration Number: NCT06491394

Saline Enema Administration in Meconium Obstruction of Prematurity and Impact on the Resolution, Feeds, Microbiome, and Gut-brain Axis.

Not Applicable

Recruiting

Conditions: Meconium Obstruction of Prematurity

Interventions: Drug: Glycerin Suppository
Procedure: Saline Enema (SE)

First Posted Date: 2023-09-21

Last Posted Date: 2024-03-12

Lead Sponsor: KK Women's and Children's Hospital

Target Recruit Count: 95

Registration Number: NCT06048614

Locations: 🇸🇬
KK Women's and Children Hospital, Singapore, Singapore

Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen

Phase 4

Recruiting

Conditions: Constipation

Interventions: Drug: PEG 3350
Drug: PEG-3350 with electrolytes
Drug: Glycerin

First Posted Date: 2023-04-20

Last Posted Date: 2024-08-05

Lead Sponsor: Indiana University

Target Recruit Count: 50

Registration Number: NCT05821309

Locations: 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
IU North Hospital, Carmel, Indiana, United States

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Phase 2

Active, not recruiting

Conditions: Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment

Interventions: Drug: Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]

First Posted Date: 2022-12-21

Last Posted Date: 2024-07-30

Lead Sponsor: Wills Eye

Target Recruit Count: 80

Registration Number: NCT05660447

Locations: 🇺🇸
Wills Eye Physicians - Mid Atlantic Retina, Philadelphia, Pennsylvania, United States

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

Not Applicable

Completed

Conditions: Dry Eye Disease

Interventions: Drug: glycerin 0.7%/PEG 400 0.3%
Drug: polyethylene glycol 400 0.4%/propylene glycol 0.3%

First Posted Date: 2022-12-21

Last Posted Date: 2023-09-06

Lead Sponsor: Calm Water Therapeutics LLC

Target Recruit Count: 34

Registration Number: NCT05660681

Locations: 🇺🇸
Andover Research Eye Institute, Andover, Massachusetts, United States

The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear

Phase 1

Withdrawn

Conditions: Thickened Ears
Tympanosclerosis
Surgery
Healthy

Interventions: Drug: Glycerol

First Posted Date: 2022-08-11

Last Posted Date: 2024-08-21

Lead Sponsor: Nova Scotia Health Authority

Registration Number: NCT05497934

Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)

Phase 2

Conditions: Monocarboxylate Transporter 8 Deficiency

Interventions: Drug: Glycerol Phenylbutyrate 1100 MG/ML

First Posted Date: 2021-08-24

Last Posted Date: 2021-08-24

Lead Sponsor: Kaplan Medical Center

Target Recruit Count: 6

Registration Number: NCT05019417

Locations: 🇮🇱
Pediatric Endocrinology Unit, Kapan Medical Center, Rehovot, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy